Mikhail Kalinichev
Chief Executive Officer Neurosterix
Seminars
Wednesday 16th September 2026
Unravelling the Therapeutic Potential of Metabotropic Glutamate Receptor 7 (Mglu7) Negative Allosteric Modulators in Neuropsychiatric Disorders
12:15 pm
- mGlu7 is a promising target for neuropsychiatric disorders based on brain distribution, modulation of glutamatergic and GABAergic neurotransmission in the stress neural circuit and reduced anxiety-, aggressivity and depression-like reactivity of KO mice
- NTX-819, a potent and selective mGlu7 negative allosteric modulator, discovered internally, is being developed for mood disorders
- NTX-819 and related compounds, have shown promising efficacy profiles in a range of models of neuropsychiatric disorders, including isolation rearing model of schizophrenia and repeated stress-induced model of depression
